Compare Otis Worldwide Corp (OTIS) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Otis Worldwide Corp vs Tempus AI — how do they compare? Otis Worldwide Corp trades at $69.36 (market cap $26.67B), while Tempus AI trades at $61.13 (market cap $11.67B). The key difference: Otis Worldwide Corp is far larger — about 2.3× Tempus AI's market cap, and Otis Worldwide Corp pays a 2.51% dividend while Tempus AI pays none. Which is the better fit depends on your goals.
| OTIS | TEM | |
|---|---|---|
Market Cap | $26.67B | $11.67B |
Sector | Industrials | Broad Market / Factor |
52-Week High | $93.62 | $103.25 |
52-Week Low | $69.30 | $41.55 |
Enterprise Value | $34.70B | $12.30B |
Dividend Yield | 2.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Otis Worldwide (OTIS) trades at $70.06, down 1.61% on the day, amid a bearish technical signal and recent earnings misses. The stock shows a P/E of 18.01 and P/S of 1.83, with strong cash flow from operations of $1.60B in 2025 but a negative net cash flow of -$1.22B. Recent news includes a dividend declaration and new contracts in China, while technical indicators highlight support near $70 and an oversold RSI.
The outlook is mixed: analyst consensus is a Buy with a $92.50 price target, implying upside, but risks include high debt-to-asset ratio of 75.54% and margin pressure from labor costs. Service segment growth offers stability, yet weak new equipment demand and guidance cuts temper near-term optimism.
Tempus AI (TEM) trades at $64.29, down 0.51% on the day, with a bullish technical signal and strong analyst support. The stock shows consistent earnings beats despite negative profitability, with a P/S of 7.99 and P/B of 26.23. Recent catalysts include FDA clearance for an AI ECG product and a $9.5 million ARPA-H award for autonomous AI in cardiology (Business Wire, September 9, 2026).
Outlook remains positive given analyst consensus and growth in precision medicine, but risks include sustained losses, high valuation multiples, and cash burn. The consensus price target is $69.11, implying potential upside, though investors must weigh the company's unprofitability against its innovation pipeline and market position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
